As Democrats continue fighting to bring down costs, pharmaceutical company takes major step in right direction
Today, Eli Lilly, the largest manufacturer of insulin in the United States, announced it will follow Democrats’ lead and cap the cost of insulin at $35 per month for consumers on private insurance.
Eli Lilly’s move is a result of House Democrats and President Biden applying pressure on Big Pharma to rein in prices on life-sustaining medication and comes after Democrats capped the cost of insulin at $35 per month for seniors on Medicare through the Inflation Reduction Act.
When given the opportunity to cap insulin prices, every Republican in Congress voted against it. Now, some MAGA House Republicans have made calls and efforts to repeal the cost-reducing legislation.
DCCC Spokesperson Tommy Garcia:
“Democrats’ steadfast efforts to lower prices stand in clear contrast to Republicans, who sought to stop and now want to repeal legislation that capped insulin at $35 per month for seniors on Medicare. Americans who benefit from the Inflation Reduction Act or Eli Lilly’s recent insulin price reduction will be reminded that House Republicans think they should be paying more for their life-saving medication.”
###
Please make sure that the form field below is filled out correctly before submitting.
